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Abstract
Background: Live attenuated simian immunodeficiency virus (SIV) vaccines represent the most effective means of
vaccinating macaques against pathogenic SIV challenge. However, thus far, protection has been demonstrated to be more
effective against homologous than heterologous strains. Immune correlates of vaccine-induced protection have also been
difficult to identify, particularly those measurable in the peripheral circulation.
Methodology/Principal Findings: Here we describe potent protection in 6 out of 8 Mauritian-derived cynomolgus
macaques (MCM) against heterologous virus challenge with the pathogenic, uncloned SIVsmE660 viral stock following
vaccination with live attenuated SIVmac251/C8. MCM provided a characterised host genetic background with limited Major
Histocompatibility Complex (MHC) and TRIM5a allelic diversity. Early protection, observed as soon as 3 weeks post-
vaccination, was comparable to that of 20 weeks vaccination. Recrudescence of vaccine virus was most pronounced in
breakthrough cases where simultaneous identification of vaccine and challenge viruses by virus-specific PCR was indicative
of active co-infection. Persistence of the vaccine virus in a range of lymphoid tissues was typified by a consistent level of SIV
RNA positive cells in protected vaccinates. However, no association between MHC class I /II haplotype or TRIM5a
polymorphism and study outcome was identified.
Conclusion/Significance: This SIV vaccine study, conducted in MHC-characterised MCM, demonstrated potent protection
against the pathogenic, heterologous SIVsmE660 challenge stock after only 3 weeks vaccination. This level of protection
against this viral stock by intravenous challenge has not been hitherto observed. The mechanism(s) of protection by
vaccination with live attenuated SIV must account for the heterologous and early protection data described in this study,
including those which relate to the innate immune system.
Citation: Berry N, Ham C, Mee ET, Rose NJ, Mattiuzzo G, et al. (2011) Early Potent Protection against Heterologous SIVsmE660 Challenge Following Live
Attenuated SIV Vaccination in Mauritian Cynomolgus Macaques. PLoS ONE 6(8): e23092. doi:10.1371/journal.pone.0023092
Editor: Esper Georges Kallas, University of Sao Paulo, Brazil
Received February 23, 2011; Accepted July 5, 2011; Published August 10, 2011
Copyright:  2011 Berry et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the UK Medical Research Council (G9025730, G9419998, G0600007 and G0801172), EUFP6 grant Europrise
(037611), the National Institute for Health Research (NIHR) Centre for Research in Health Protection at the Health Protection Agency, and the UCL/UCLH NIHR
Comprehensive Biomedical Research Centre. GT holds a Wellcome Trust senior fellowship (no 090940). This report is work commissioned by the National Institute
for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the National
Institute for Health Research or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: neil.berry@nibsc.hpa.org.uk
Introduction
The development of safe, effective vaccination strategies to
control the HIV/AIDS pandemic remains an important goal for
global human health, although significant obstacles to achieving
this aim remain following disappointing results from recent Phase
II/III clinical HIV vaccine trials [1]. Candidate HIV vaccine
design is further compounded by the diverse sequence variation
which characterises the worldwide spread of HIV, represented by
multiple HIV-1 groups (M, N and O), further divided into multiple
subtypes or clades and complex recombinant forms [2,3]. Ideally,
vaccination would prevent infection completely or reduce onward
virus transmission, although the appropriate responses needed to
be induced by an effective HIV vaccine strategy to prevent
infection remain unclear. Vaccination with live attenuated SIV
vaccines in the SIV/macaque model have consistently demon-
strated potent vaccine protection from wild-type virus challenge
[4] either to protect completely from detectable infection, or
reduce markedly the replication of the challenge virus adminis-
tered by either the intravenous or mucosal routes [5–30]. Yet even
within these model systems discrepancies exist regarding the
outcome of vaccine/challenge studies using this vaccine approach.
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In particular, there is uncertainty as to the potency of vaccine
protection against heterologous virus challenge.
Although the use of live attenuated retroviruses as vaccines
suitable for human use is precluded on safety grounds [31,32,33],
with both reversion of the attenuated virus vaccine to wild-type
[28] and recombination with challenge virus [18,34] having been
described, the identification and reproduction of protective
vaccine responses by safer means remains an important goal of
HIV vaccine research. While the outcome of live attenuated
vaccine studies may be dependent on different variables such as
the vaccine strain and duration of vaccination, the challenge virus
and its biological properties in vivo and the host species, analysis of
these variables and their influence on study outcomes provides the
opportunity to identify processes by which this vaccination
approach protects.
We have been characterising the protection conferred by a nef-
disrupted viral clone derived from SIVmac251/32H, designated
SIVmacC8 [35]. In previous vaccine studies we have demonstrat-
ed the ability of SIVmacC8 to protect from both a moderately
replicating, cloned virus challenge (SIVmac32H/J5) [7,24,25] and
a vigorously replicating, uncloned homologous challenge stock
(SIVmac251/32H/L28) [8]. While protection has been observed
as early as 21 days post-vaccination against SIVmac251/J5
[24,25], protection is superior after longer periods of vaccination,
up to 20 weeks, particularly against the SIVmac251/32H/L28
stock [8]. Although protection conferred by SIVmacC8 against
SIVmacJ5 coincides with the appearance of detectable CD8+ T
cell responses [24] it does not appear to be abrogated by profound
CD8+ T cell depletion [25], nor can protection be transferred by
immune serum [36]. Despite having different biological properties
in vivo, both virus challenge stocks in these studies were genetically
homologous to the SIVmac251/C8 vaccine strain.
Therefore, to extend these studies, the breadth of vaccine
protection conferred by SIVmacC8 was assessed by challenging
with an antigenically and genetically distinct virus stock. The
uncloned SIVsmE660 virus stock has been used in studies of
Indian rhesus macaques (Macaca mulatta) vaccinated with
SIVmac239D3 [29] and SIVmac239Dnef [18] vaccines.
SIVsmE660 is considered to represent a genetically diverse,
heterologous virus challenge stock containing multiple sequences
in a viral swarm having undergone only minimal passage in rhesus
macaques (RM).
Recent developments in the immunogenetic characterisation of
Mauritian cynomolgus macaques (MCM), which express limited
genetic diversity, have identified their valuable place to study the role
of host MHC genetics in immunogenicity and vaccine studies [37–
45]. Only 7 MHC haplotypes encompassing Class IA, IB and MHC
Class II DR, DP and DQ regions, are present in MCM at
frequencies .1% [37,38]. The relative ease of MHC haplotype
characterisation and high frequency of selected MHC haplotypes
have enabled small retrospective population studies to be performed.
Statistically robust associations between M3 or M6 haplotypes and
superior viraemic control of SIV or SHIV viruses in naı¨ve-
challenged and vaccinated individuals have been identified [43–45].
Since relatively little is known about the infectivity and
replication properties of SIVsmE660 in MCM, and to establish
the infectious titre of this stock in this species, an in vivo titration
was performed. Subsequently, a vaccine study was conducted to
determine if vaccination of Mauritian-derived cynomolgus ma-
caques with SIVmacC8 could protect against SIVsmE660
challenge. The outcome of the vaccine study was interpreted in
the knowledge of the replication dynamics of SIVsmE660 in
unvaccinated MCM and the potential influence of MCM MHC
genetics and TRIM5a polymorphism on vaccine protection in this
system. In keeping with previous studies [24,25,8], we compared
the effects of vaccination with SIVmacC8 for 3 and 20 weeks prior
to SIVsmE660 challenge.
Here we demonstrate that vaccination of naive MCM with
SIVmacC8 prevents detectable infection against challenge with
the heterologous, pathogenic SIVsmE660 challenge stock in a high
proportion of vaccinates, irrespective of the MHC genetic
background of the host. Potent vaccine protection was established
as early as three weeks with no difference between 3 and 20 week
vaccine regimens. Understanding how such early protection is
generated with live attenuated SIV in this model system will
inform HIV/AIDS vaccine design.
Results
Infectivity and RNA kinetics of the SIVsmE660 challenge
stock in MCM
The infectivity and in vivo titre of the SIVsmE660 virus stock in
Mauritian cynomologus macaques was first determined (Figure 1).
In an initial titration series groups 1–4, (B1–B8; 1/10–1/100,000
dilutions), productive infection was established in all macaques as
determined by viral RNA (vRNA) analysis and virus co-culture
(Figure 1A; Table S1), although no end-point was reached. Plasma
vRNA peaked in B1-B6 at day 10 but was slightly delayed (,day
14) in B7 and B8. In a second series, groups 5–7 (B95–B100; 1/
10,000–1/1,000,000 dilution; Figure 1B), productive infection was
established in 2/2 inoculated with 1/10,000 dilution (B95, B96),
1/2 with 1/100,000 dilution (B98) and 0/2 with 1/1,000,000
dilution (Figure 1B, Table S1). Virus replication kinetics in B95,
B96, B98 were very similar to each other and challenges with
lower virus dilutions; B97, B99 and B100 remained vRNA
undetectable with no evidence of transient or late infection.
Of 11 naı¨ve macaques productively infected with SIVsmE660,
mean day 14 and 84 viraemia levels were 6.9160.14 log10 and
5.9560.16 log10 SIV RNA copies/ml respectively, demonstrating
high, reproducible infectivity and replication potential of the
SIVsmE660 challenge stock in MCM. Viral RNA kinetics in
productively infected individuals were virtually identical irrespective
of challenge dose (Figure 1), the second highest vRNA titre at day 14
(B98; 7.62 log10 SIV RNA copies/ml), challenged with 1/100,000
virus dilution. Titration results indicate a MID50 for the SIVsmE660
challenge stock in MCM to be represented by 1/100,000 dilution of
the initial virus stock. Hence, 10 MID50 (1/10,000 dilution of the
original SIVsmE660 stock) was used in the subsequent vaccine study.
MHC haplotype frequency in MCM
Host MHC immunogenetic background of all 26 MCMs is
presented pictorially in Figure 2. All major previously described
MCM haplotypes (M1–M6) for MHC Class IA, Class IB and
Class II regions were represented in either the MCM in the in vivo
titration (B1–B8; B95–B100; Figure 2A) or vaccine study (B202–
B213, Figure 2B). No relationship between the ability of
SIVsmE660 to replicate in vivo in naive MCM and host MHC
haplotype frequency was identified. High levels of peak and
persisting plasma vRNA loads in productively infected naive
MCM challenged with SIVsmE660 occurred irrespective of MHC
haplotype combination, including recombinants (Figure 1). The
slight delay in the vRNA peak at 14 days in B7 and B8 challenged
with 10 MID50 of virus compared with B1–B6 where the peak was
10 days post infection, yet B7 had an identical MHC profile to B2
(haplotypes M3/M4). Hence, among naive MCM, MHC
haplotype did not appear to affect peak or persisting viral loads,
though robust statistical analyses were confounded by low
frequency of haplotypes M5 and M6 in the study cohort.
Heterologous SIV Vaccine Protection
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Figure 1. Infectivity of SIVsmE660 challenge stock in Mauritian cynomolgus macaques. Levels of plasma SIV RNA measured by qRT-PCR
with R/U5 primers following multiple SIVsmE660 challenges in an in vivo titration of unvaccinated Mauritian cynomolgus macaques. Red arrow shows
point of SIVsmE660 inoculation (day 0). Plasma SIV RNA levels are shown for individual macaques (B1–B8) and (B95–B100) in two independent
titration series (panels A and B respectively) comparing acute, peak and steady-state chronic phases of virus replication post-SIVsmE660 challenge.
Outcome of administering high dose (low dilution) viral inocula for pairs of macaques receiving a 1/10 (Group 1 ; B1, B2), 1/100 (Group 2; B3, B4); 1/
1000, (Group 3, B5, B6), and 1/10,000 (Group 4, B7, B8) dilution of virus are shown in panel A. Plasma viraemia for the second dilution series at 1/
10,000 (Group 5; B95, B96), 1/100,000 (Group 6; B97, B98) and 1/1,000,000 (Group 7, B99, B100) dilutions are shown in panel B. No evidence of plasma
virus was detected in B97, B99 and B100 at any time point.
doi:10.1371/journal.pone.0023092.g001
Heterologous SIV Vaccine Protection
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TRIM5a polymorphism
The TRIM5a/TRIM-Cyp genotype was determined for all 26
MCM in this study (Table 1). Only 3 distinct TRIM5a genotypes
were identified. The Mamu4 genotype [46] was present in all 26
macaques, most commonly as a homozygous genotype in 14 out of
26 (54%) MCM or as heterozygous 4/8 or 4/9 genotype in 6 out
of 26 (23%) respectively. TRIM5a alleles were relatively evenly
distributed between both the titration and vaccine studies (Table 1).
No TRIM-Cyp variants were identified. These data concur with
other unpublished findings (NB, GJT, NR). Although only
represented by three TRIM5a variants, in unvaccinated macaques
there appeared to be no confounding influence of TRIM5a
polymorphism on SIVsmE660 replication in this study population,
with all unvaccinated macaques challenged with SIVsmE660
displaying very similar plasma viral RNA kinetics in vivo.
SIVmacC8 vaccine kinetics
Eight MCM were inoculated by intravenous injection with 5000
TCID50 SIVmacC8. Plasma SIV RNA levels were monitored by a
quantitative real-time gag PCR assay (Groups A and B; Figure 3).
All eight vaccinates were productively infected with SIVmacC8.
Group A, vaccinated for 20 weeks (Fig 3A), all displayed similar
levels of plasma viraemia at 14 days post-inoculation (4–5 log10
SIV RNA copies/ml), comparable with historical data with this
virus vaccine [8,47]. Analysis of vaccine virus kinetics over the 20
week vaccination period indicated one of three steady-state vRNA
profiles: i) enhanced control of SIVmacC8 viraemia (B204) to
undetectable levels at time of SIVsmE660 challenge ii) typical
reductions in viraemia from the peak declining to similar levels
(B203, B205), returning to baseline levels, iii) low, persisting vRNA
levels (B202) at ,3 log10 SIV RNA copies/ml. At time of
SIVsmE660 challenge SIV RNA levels were #103 copies/ml in all
vaccinates.
Differences in vRNA levels in 20 week vaccinates (Group A,
B204–B205) also appeared unrelated to MHC haplotype compo-
sition (Figure 2B). All were positive for haplotype M1 in the Class
IA region. Group B (Figure 3B), vaccinated with SIVmacC8 for
three weeks all had quantifiable viraemia at time of SIVsmE660
challenge at levels also consistent with previous SIVmacC8
vaccinations.
Figure 2. Distribution of MHC haplotypes in 26 Mauritian cynomolgus macaques. MHC genotype distribution for the in vivo titration of
SIVsmE660 (see Figure 1) in macaques B1–B8 and B95–B100 (panel A). Twelve macaques (B202–B213) were included in the vaccine/challenge study
(panel B). Distribution of M1–M6 haplotypes for Class IA, Class IB and Class II for each animal is shown in pictorial format represented as: M1 (black);
M2 (red); M3 (blue), M4 (green), M5 (yellow) and M6 (grey). No M7 haplotype was identified. Recombinants are represented as multiple colours.
doi:10.1371/journal.pone.0023092.g002
Heterologous SIV Vaccine Protection
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Antibody levels post SIVmacC8 vaccination
All 20 week SIVmacC8 vaccinates (Group A) exhibited similar
binding antibody profiles against rgp130 (Figure 4A, B), typical for
this vaccine. At day of SIVsmE660 challenge, anti-SIVrgp130
levels were ,2.5 log10 in all 20 week vaccinates. Anti-gp130 titres
were more variable among three week vaccinates (Group B), with
no response detected in B206 prior to SIVsmE660 challenge
(Figure 4B). Neutralising antibody titres were assessed retrospec-
tively with SIVmac251/J5, representing the vaccine virus and
SIVsmE660 the challenge virus (Table 2). On the day of
SIVsmE660 challenge neutralising antibody titres were undetect-
able (,1.0 log10) for both Groups A and B, against SIVsmE660.
For SIVmac251/J5, neutralisation titres were detected in all 20
week vaccinates (Group A), although at low levels (2.13, 2.20, 1.90
and 1.98 log10 for B202–B205 respectively) but were undetectable
(,1.0 log10) in 3 week vaccinates (Group B).
CD4 lymphocyte counts
CD4 lymphocytes were monitored during vaccination and
challenge periods (Figure 5). Prior to SIVmacC8 inoculation,
mean percentages of CD4+ lymphocytes in all MCM were within
the 30–40% reference range. In 335 naı¨ve cynomolgus macaques
analysed retrospectively this was 35.967.3 (SD) where the CD4+
T cell range62SD was 21.4–50.4% representing a 95%
distribution of the data. Significant immunological abnormalities
were considered to have occurred when sustained CD4 cells fell
below 21%. SIVsmE660 infection of naive MCM (Group C) led to
an overall reduction in circulating CD4+ lymphocyte percentages
(Figure 5C) which were preserved in Group A vaccinates.
Individual CD4 percentages (Figure 5A–C) displayed a wide
variation though there were distinct trends, with CD4 counts in all
Group A vaccinates being well preserved irrespective of the
challenge outcome (Figure 5A). Group B showed more variation,
in particular B209 which exhibited a precipitous drop in CD4
counts after 20 weeks SIVsmE660 infection (Figure 5B), compa-
rable to unvaccinated challenge controls (Figure 5C). Interestingly,
CD4 counts appeared to be declining prior to SIVsmE660
challenge in this macaque. Individual values were reflected in the
overall group mean data (Figure 5D).
Total levels of plasma SIV RNA post-SIVsmE660 challenge
Although similar vRNA kinetics between different naive MCM
challenged with widely ranging doses of SIVsmE660 were noted
(Figure 1), comparisons of outcome of vaccinates were compared
with unvaccinated controls that received 10 or 1 MID50 virus only
representing the most biologically relevant challenge doses.
Figure 6 shows total plasma SIV RNA levels, measured by real-
time R/U5 qRT-PCR, for 20 and 3 week vaccine groups
(Figure 6A,B respectively) and nine productively infected
SIVsmE660 control macaques receiving 1–10 MID50 SIVsmE660
(Figure 6C). Acute plasma vRNA levels in controls were 6.6260.4
log10 SIV RNA copies/ml (day 14) and steady-state levels of
5.6960.35 log10 SIV RNA copies/ml (day 84).
With the exception of B204 (Group A) vaccinated for 20 weeks,
all other vaccinates had marked reductions in acute SIV RNA levels
14 days post SIVsmE660 challenge compared with naive challenge
controls (Figure 6C). By this overall marker of virus replication a
strong vaccine effect in acute and chronic control of SIVsmE660
challenge detectable in peripheral blood in both 20 and 3 week
vaccinates, compared with naive challenge controls, was observed.
Virus replication remained under control in all vaccinates,
except B204 which had higher acute and persisting vRNA loads
(7.01 and 6.95 log10 SIV RNA copies/ml, 14 and 84 days
respectively) and B209 where viraemia increased over a 20 week
period in the 5–6 log10 range. Taking together data for the eight
vaccinates and eight unvaccinated controls challenged only with
10 MID50 SIVsmE660, statistically highly significant reductions
(95% CI) in both peak (d14; p,0.005 Mann-Whitney) and
persisting (d84, p,0.005 Mann-Whitney) viraemia post
SIVsmE660 challenge were observed. For individual vaccine
groups, virus levels were 3.0961.35 log10 and 3.0561.33 log10
SIV RNA copies/ml (Group A) and 2.3360.81 log10 and
2.5461.04 log10 SIV RNA copies/ml (Group B) at 14 and 84
days post SIVsmE660 challenge respectively. However, a
proportion of this total figure could also be due to detection of
the vaccine virus, particularly in 3 week vaccinates, since the R/
U5 assay was demonstrated to be efficient at detecting both
SIVmac251 and SIVsmE660 sequences (Figure 7A).
Virus-specific real-time PCR
To elucidate virus-specific responses, type-specific PCR assays
were applied. Initial experiments indicated the published gag real-
time PCR assay [8] while efficient at detecting SIVmac251
sequences, did not detect SIVsmE660/E543 variants. Therefore a
comparable gag-based SIVsmE660-specific assay was developed to
enable delineation of individual virus infection kinetics. Using
sequences available in the Los Alamos sequence database, (www.
lanlhiv.gov) and ,700bp gag sequence recovered from unvacci-
nated SIVsmE660 challenged macaques, primer and probe
sequences for specific amplification of SIVsmE660 sequences by
real-time PCR were designed. Initial work-up experiments
identified sequences which did not cross-react with the heterolo-
gous vaccine strain SIVmacC8 (data not shown). A SIVmac251-
based RNA reference panel was used in parallel to a SIVsmE660
plasma series constructed from a pool of high titre plasma derived
from unvaccinated SIVsmE660 controls from the titration
experiment, diluted similarly in negative macaque plasma
(Figure 7A).
Table 1. Frequency and distribution of TRIM5a alleles in
unvaccinated controls and SIVmacC8 vaccinates challenged
with SIVsmE660.
Group Allele4 Allele4/8 Allele4/9
Controls B5 B1 B2
B7 B3 B4
B95 B100 B6
B96 B210 B8
B98 B211 B97
B99 (n = 5) (n = 5)
B212
B213
(n = 8)
Vaccinates B202 B207 B205
B203 (n = 1) (n = 1)
B204
B206
B208
B209
(n = 6)
The number of macaques in each group is indicated (n).
doi:10.1371/journal.pone.0023092.t001
Heterologous SIV Vaccine Protection
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Each dilution series was first compared with the R/U5 qPCR
assay demonstrating equivalent regression curves (r2 = 0.997)
across ,6 log10 dynamic range, using RNA extracted from either
the SIVmac251 or SIVsmE660 plasma dilution series (Figure 7A)
and provided a basis to compare virus-specific RT-PCR assays.
Using these independent dilution panels, the virus specificity of the
Figure 3. Vaccine virus kinetics. Kinetics of virus replication post-SIVmacC8 vaccination measured by SIVmac251/C8-specific quantitative RT-PCR
in 20 weeks (Group A) and 3 weeks (Group B) vaccinates. Blue arrow shows point of SIVmacC8 inoculation, red arrow point of SIVsmE660 challenge.
Differences in vaccine kinetics between vaccinates in Panel A, Group A (B202–B205), after the peak of virus replication was seen, prior to SIVsmE660
challenge. Panel B, shows a single time-point 21 days post SIVmacC8 inoculation, ie day of SIVsmE660 challenge. In both Groups A and B,
recrudescence of the vaccine virus SIVmacC8 upon SIVsmE660 challenge is shown.
doi:10.1371/journal.pone.0023092.g003
Heterologous SIV Vaccine Protection
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two gag-based assays were determined (Figures 7B, C). These data
indicate no evidence of cross-reactivity in the heterologous assay,
even at high viral titres (.7 log10 SIV RNA levels). Both
SIVsmE660 and SIVmac251-specific assays exhibited comparable
detection sensitivity at 50 SIV RNA copies/ml plasma.
Comparable data were generated for quantitative DNA (qDNA)
determinations, optimised on high copy number SIVsmE660 DNA
diluted to an extinction end-point in herring sperm carrier DNA. A
linear relationship between target input DNA and signal was
demonstrated (not shown). Assay specificity was further established
by cross-titration of high copy number input SIVmac251 and
SIVsmE660 DNA, capable of detecting single copies of SIVsmE660
DNA in a background of 100,000 cell equivalents of genomic DNA.
These assays were applied to plasma vRNA and tissue qDNA
estimations of viral copy number in the vaccine study.
Absence of SIVsmE660 RNA and DNA in protected
vaccinates
Levels of SIVsmE660-specific RNA in plasma and SIVsmE660
DNA (Figures 8 and 9 respectively) in blood and lymphoid tissues in
vaccinates (B202–B209) and unvaccinated challenge controls
(B210–B213) assessed post-mortem were determined. This identi-
fied the ability of vaccination with SIVmacC8 after 3 or 20 weeks to
resist SIVsmE660 challenge. Application of the SIVsmE660-specific
vRNA assay to all plasma samples collected post-SIVsmE660
challenge separated the vaccinates out into those where vRNA was
undetectable (Group A; B202, B203, B205 and Group B; B206,
B207, B208), suggesting protection, and those superinfected with
SIVsmE660 (B204, Group A; B209, Group B), Figures 8A,B,
compared to unvaccinated challenge controls analysed with the
same SIVsmE660-specific assay (Figure 8C). No evidence of late
breakthrough, or transient spikes in SIVsmE660 RNA signal, was
detected in these six protected vaccinates.
These data were supported by analysis of mononuclear cell
(MNC) DNA with SIVsmE660-specific qDNA PCR of blood and
lymphoid tissues. In 3 out of 4 vaccinates in each group, no
evidence of SIVsmE660 DNA was detected in B202, B203, B205
(Group A) or B206, B207, B208, (Group B) at ,1 copy
SIVsmE660 DNA/100,000 MNC DNA (Figure 9). In superin-
fected vaccinates B204, B209, high levels of SIVsmE660 DNA
were detected at comparable levels to unvaccinated challenge
controls (B210, B211 B212, B95, B96, B98, B7, B8) where 100–
1000 SIVsmE660 DNA copies/100,000 MNCs were typical. B213
remained SIVsmE660 DNA PCR negative in the tissues sampled.
Overall, no evidence of SIVsmE660 sequences were detected in 6/
8 SIVmacC8 vaccinates post SIVsmE660 challenge in peripheral
blood or lymphoid tissues including spleen, mesenteric and
peripheral lymph nodes (MLN, PLN). Interestingly, SIVsmE660
DNA levels in tissues in B98, challenged with 1MID50 virus at the
infection threshold, exhibited comparable levels of DNA in tissues
to the other controls.
Figure 4. Anti-gp130 levels. Anti-gp130 levels post-SIVmacC8 vaccination and post SIVsmE660 challenge determined by binding antibody ELISA,
(day 0 represents day of SIVsmE660 challenge) shown for Groups A, B and C. Group A shows anti-SIVmacC8 gp130 levels for 20 weeks prior to
SIVsmE660 challenge (at day 0) with an anamnestic response detected in B204. Panel B shows anti-gp130 responses in Group B (3 week vaccinates)
and Group C (SIVsmE660 naı¨ve challenge controls) respectively.
doi:10.1371/journal.pone.0023092.g004
Table 2. Neutralising antibody titres on day of SIVsmE660
challenge.
ID SIVmac251 SIVsmE660
Group A B202 2.13 ,1.0
B203 2.20 ,1.0
B204 1.90 ,1.0
B205 1.98 ,1.0
Group B B206 ,1.0 ,1.0
B207 ,1.0 ,1.0
B208 ,1.0 ,1.0
B209 ,1.0 ,1.0
Log10 neutralising antibody titres on day of SIVsmE660 challenge are shown for
Group A and Group B vaccinated for 20 and 3 weeks respectively with
SIVmacC8. ,1.0 log10 represents undetectable levels. ID = macaque identity.
doi:10.1371/journal.pone.0023092.t002
Heterologous SIV Vaccine Protection
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Evidence of vaccine virus recrudescence in vaccinates
challenged with SIVsmE660
Vaccine virus recrudescence was detected by the SIVmac251-
specific PCR indicative of vaccine re-stimulation in both
superinfected and protected vaccinates (Figure 8D,E). However,
these were generally at low levels (,1000 SIV RNA copies/ml),
shown as a continuum in Figure 3. Lack of reactivity of the
SIVmacC8-specific RT-PCR assay at high SIVsmE660 RNA
copy number (Figure 8F) confirmed signals detected in
vaccinates post-SIVsmE660 challenge to be a true representa-
tion of the vaccine virus kinetics. Superinfected macaque B204
exhibited the highest levels of vaccine virus restimulation which
also supported the highest level of SIVsmE660 replication post-
challenge.
Figure 5. CD4 lymphocyte percentages. CD4 lymphocyte percentages are shown for 20 week SIVmacC8 vaccinates (Group A; panel A) or 3
weeks (Group B; panel B), following SIVsmE660 challenge and unvaccinated challenge controls (Group C; panel C). Timings of all bleeds were taken
from initial time of SIVsmE660 challenge (day 0). Group mean values with SE of the mean values are shown in panel D.
doi:10.1371/journal.pone.0023092.g005
Heterologous SIV Vaccine Protection
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Distribution of SIV positive cells in lymphoid tissues by in
situ hybridisation
Distribution of SIV RNA positive cells post-mortem was
determined by in situ hybridisation in the vaccine study. Since
ISH probe sequences were unable to differentiate between vaccine
and challenge virus strains, vaccinates and controls were
compared for total SIV RNA. Amongst unvaccinated SIVsmE660
controls challenged for 20 weeks, the frequency of virus-producing
cells ranged between 0.5–6.8 SIV RNA positive cells/mm2 in most
tissues except B210/B212 (MLN) and B212/B213 (spleen) as
summarised in Table 3. In the six protected vaccinates at either 40
or 23 weeks post-SIVmacC8 vaccination, SIV positive cells were
evenly distributed in all tissues sampled (spleen, MLN, PLN, small
intestine, thymus), although frequencies were relatively low
(Table 3). Figures 10A and B shows the distribution of SIV
RNA positive cells in protected vaccinates B202/B207 (MLN) and
a higher frequency of SIV positive cells in superinfected vaccinates
B204/B209 (Figure 10C,D). These compare with challenge
controls B210 (Figure 10E) and B213 (Figure 10F) for the MLN
and small intestine respectively.
No impact of MHC genotype on challenge outcome in
vaccinates
Of the 12 MCM vaccinated with SIVmacC8 a high frequency
(50%) were positive for MHC haplotype M1. Several MCM
carried recombinant haplotypes comprising elements of M1 and
other haplotypes. B6 was the only individual possessing MHC
haplotype M6 in both Class I and Class II regions; B212 was
positive for M6 in class IA only. Interestingly, steady-state vRNA
loads in control macaque B212 (M6; Class 1A region) challenged
with SIVsmE660 was approximately 0.5 log10 SIV RNA copies/
ml lower than mean values. Of the two vaccinates superinfected
with SIVsmE660, B204 was MHC-identical to B5 (M1/M2–M1
recombinant), productively infected in the in vivo titration. An
identical genotype to macaque B209 (M3–M1/M3 recombinant)
was not present among the other vaccinates though each
constituent element of these haplotypes were present in at least
one other vaccinate (Figure 2). Finally, the altered infection
dynamics in B213 did not appear to be linked to its MHC, since its
genotype (M3/M4) was identical to those of B2/B7, both of whom
were productively infected with SIVsmE660. B99 (M3/M4),
which received less than the minimum dose of SIVsmE660
required to establish infection, remained SIV RNA negative.
Overall, no correlation between MHC immunogenotype and
outcome of the vaccine study was identified.
No influence of TRIM5a genotype on vaccine outcome
Similarly, although numbers were too small to apply statistical
analysis, there was no overt association with any of the three
TRIM5a alleles identified and outcome of the vaccine study.
Indeed, the two breakthrough vaccinates (B204, B209) both
carried the homozygous Mamu4 genotype [46], as did four other
vaccinates evenly distributed between vaccine groups, and eight
unvaccinated macaques challenged with varying doses of
SIVsmE660 (Table 1). These data indicate there is no apparent
confounding factor influencing vaccine outcome relating to
TRIM5a polymorphism in this study.
Discussion
Intensive research efforts to develop a successful prophylactic
HIV vaccine have so far proved largely unsuccessful. In macaque
models of HIV vaccines, live attenuated SIV elicits robust
protection against challenge strains homologous to the vaccine
[4], although only limited protection against intravenous challenge
with heterologous isolates genetically distinct to the vaccine virus
Figure 6. Total SIV RNA levels in plasma. SIV RNA levels, expressed as log10 SIV RNA copies/ml, determined by virus-common qRT-PCR assay
based on conserved R/U5 sequences in genomic SIV RNA. Panel A, 20 weeks vaccinates (Group A; B202–B205); panel B, 3 weeks vaccinates (Group B;
B206–B209); panel C, 9 naive controls challenged with low dose (1–10MID50) SIVsmE660.
doi:10.1371/journal.pone.0023092.g006
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have been reported [29,18]. Clear correlates of vaccine-induced
protection across different studies have proved difficult to identify
[7–9,12,14,19,22,24,25,29,30], hence the immune responses
needed to be generated by a successful vaccine remain poorly
understood. This study, conducted in Mauritian-origin cynomol-
gus macaques, describes early potent protection against the
heterologous, vigorously replicating SIVsmE660 challenge stock
following vaccination with the minimally attenuated SIVmac251/
Figure 7. Type common and type specific PCR analysis of SIVmac251 and SIVsmE660. Panel A shows equivalent amplification of
SIVmac251 and SIVsmE660 with R/U5 primers targeting the 59 region of genomic SIV RNA. Comparable regression curves were obtained with a high
titre SIVmac251 reference panel [65] and a SIVsmE660 plasma pool derived from day 10 and 14 bleeds of titration macaques B1–B4. Subsequent
cross-titration experiments conducted with the heterologous gag-based SIVsmE660 and SIVmacC8 plasma viral RNA quantification assays compared
threshold detection levels with viral RNA in-put copy number. Assay specificity was demonstrated with the same pooled SIVsmE660 plasma from
control MCMs diluted in negative plasma and a SIVmac251/L28 plasma reference panel [65] for SIVmac251 sequences. Respective assays
demonstrated specific amplification of the SIVsmE660 (challenge, panel B) and SIVmac251 (vaccine, panel C) viruses by gag-specific RT-PCR across a 6
log10 dynamic range. Intra-assay variation between replicates of the SIVsmE660-specific assay was 0.09 SD with a minimum amplification efficiency of
94.9%. Replicates included at least three runs with a coefficient of variation of ,3%. No cross-reactivity with the heterologous virus was detected
above a sensitivity of detection limit of 50 SIV RNA copies/ml.
doi:10.1371/journal.pone.0023092.g007
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C8 vaccine [35]. Cynomolgus macaques provided consistency
with previous studies characterising the protective vaccination
conferred by SIVmacC8 [7,8,23–25].
Mauritian-derived cynomolgus macaques also provided a way to
control for host MHC genetics [37–45]. Possible confounding non-
MHC genetic factors such as TRIM5a polymorphism were also
investigated. Against this genetic background the infectious titre and
replication kinetics of the SIVsmE660 challenge stock, used without
further passage, were determined. In naive MCM, SIVsmE660
established high peak primary viraemia and a higher persisting
steady-state infection than reported for Indian RM after delivery by
the intravenous route [18,29,30]. Productively infected MCM
displayed essentially indistinguishable patterns of primary peak and
high, stably persisting plasma viraemia, independent of host MHC,
TRIM5a polymorphism or challenge dose. Low or limiting challenge
doses exhibited comparable plasma viral RNA profiles to higher
challenge doses. This level of chronic SIVsmE660 infection initiated
persistent depression of CD4 lymphocytes to below the normal range
in a proportion of naı¨ve, unvaccinated MCM. Hence, SIVsmE660
provided a rigorous, pathogenic heterologous challenge to evaluate
vaccine protection conferred by live attenuated SIVmacC8 in this
species, within a defined host genetic background.
Following SIVmacC8 vaccination, a high proportion (6/8) of
MCM displayed no evidence of SIVsmE660 superinfection,
determined by sensitive and specific real-time PCR assays for
SIVsmE660 RNA in peripheral blood and sequestration of
SIVsmE660 proviral DNA in lymphoid tissues. No evidence of
late breakthrough events in these apparently completely protected
vaccinates was identified. One surprising outcome was equivalent
levels of protection between 3 and 20 week vaccinates against this
heterologous, pathogenic isolate, with one breakthrough case in
each vaccine group. Unlike protected vaccinates both exhibited
high levels of SIVsmE660 vRNA, comparable to unvaccinated
challenge controls, accompanied by a boosting of anti-gp130 titres
reflecting increased antigenic stimulation in these cases of viral
superinfection. Some immunological benefit, however, was gained
from a longer vaccine regime. Profound loss of circulating CD4
lymphocytes in the three week breakthrough vaccinate (B209),
comparable to unvaccinated SIVsmE660-infected MCM, con-
trasted with more preserved CD4 lymphocyte counts in the 20
week breakthrough vaccinate (B204), despite similar levels of
SIVsmE660 viraemia.
High efficiency of intravenous transmission with this challenge
stock in MCM was further reflected in the ability to successfully
infect at the rate limiting 1MID50 challenge dose. However, it
should be noted that one control macaque in the vaccine study
challenged with the 10 MID50 dose, failed to develop a productive
infection remaining plasma vRNA and proviral DNA negative at
Figure 8. Differential vRNA analysis of SIVsmE660 and SIVmacC8 in plasma. Plasma SIV RNA levels shown for superinfected vaccinates
(B204/B209) and six protected vaccinates (B202, B203, B205, B206, B207, B208) using a SIVsmE660-specific viral RNA assay (panels A and B
respectively), compared to unvaccinated naive challenge controls (panel C) with the same assay. Controls were eight naı¨ve MCMs challenged with 10
MID50 of the SIVsmE660 stock (1/10,000 dilution of the original stock; B7, B8, B95, B96, B210–B213) or productively infected at the 1/100,000 dilution
(B98). Levels of the vaccine virus SIVmacC8 are shown in panels D and E for superinfected and protected vaccinates respectively with the SIVmac251-
specific qPCR assay [8]. Panel F shows no reactivity .50 SIV RNA copies/ml of the SIVmacC8-specific assay with unvaccinated challenge controls
sampled at 14, 84 and 140 days post SIVsmE660 challenge.
doi:10.1371/journal.pone.0023092.g008
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all times post-SIVsmE660 inoculation, although did mount a
partial anti-gp130 response and SIV RNA positive cells were
identified in lymphoid tissue. The reasons for the failure of full
virus dissemination in this control macaque are not known,
although the host genetic background of this individual did not
mark it out from other challenge controls where high, sustained
levels of productive infection were typical. Despite this, statistically
significant differences between SIVmacC8 vaccinates protected
against 10MID50 intravenous SIVsmE660 challenge compared to
SIVsmE660 controls were observed.
One of the strengths of using Mauritian-derived cynomolgus
macaques is the ability to define the haplotype across the entire
MHC region encompassing both Class I and Class II, with an
association between expression of the Mauritian M6 haplotype
and superior control of virus replication following challenge with a
stock of SIVmac251 having been demonstrated [44]. However,
there was no evidence that possession of any particular haplotype
was associated with superior or inferior control of SIVsmE660
replication in unvaccinated MCM or vaccine study outcome.
Vaccine breakthrough macaques were not atypical in their overall
MHC genetics. Similarly, the MHC genetics of control B213,
which exhibited limited replication of SIVsmE660 post-challenge,
were not unusual since B2 and B7 possessed the same M3/M4
heterozygous pattern. Hence, the ability of SIVsmE660 to
replicate in naive MCM, and subsequent challenge outcome,
appears unrelated to the MHC immunogenetic background of this
host species.
This would appear to contrast with data from Indian RM where
vaccinates expressing MHC-class I alleles associated with control
of the vaccine virus also substantially controlled acute phase
replication upon SIVsmE660 challenge, although were unable to
completely contain SIVsmE660 replication with viraemia levels
rising again in the chronic period [18]. One explanation for the
lack of association between MHC haplotype and vaccine efficacy
in the current study is the limited number in each group (eight
vaccinates of which only two were superinfected) which precludes
statistical analysis. Another possibility is that the robust replication
kinetics of SIVsmE660 in MCM, and the potent protection
afforded by SIVmacC8 vaccination, outweigh any advantage that
particular MHC haplotypes might confer against SIV infection.
Without access to larger cohorts of MCM treated with the same
vaccine/challenge virus combinations, detection of robust associ-
ations between host MHC genetics, vaccine outcome and viral
replication kinetics is statistically challenging, particularly for low-
frequency haplotypes.
The relative impact of non-MHC host genetic factors, namely
TRIM5a variation was also investigated. In RM TRIM5a is
polymorphic impacting to varying degrees on the ability of the
host to restrict virus replication in vivo, as recently shown in
cohorts of unvaccinated Indian RM inoculated with SIVmac251
[48] and SIVsmE660/E543-related viruses [49]. However, little is
known of the impact of TRIM5a genotype on SIV replication in
MCM. Sequence analysis of the variable B30.2 domain of
TRIM5a identified three distinct TRIM5a genotypes in the 26
MCM in this study, although the Mamu4 allele [46] was present in
all 26, with 54% homozygous for Mamu4 and 23% heterozygous
for Mafa4/8 and Mafa4/9 respectively. This represents a much
more limited spectrum of TRIM5a polymorphism compared to
RM and, as with the MHC, most likely reflects the small founder
population of Mauritian-origin CM. There appeared to be no
Figure 9. SIVsmE660 DNA levels in lymphoid tissues. Levels of SIVsmE660-specific DNA in lymphoid tissue in SIVsmE660 controls and 20 and 3
week SIVmacC8 vaccinates shown according to superinfection or protection status. SIV DNA levels are expressed as copies of SIVsmE660 DNA /
100,000 cell equivalents MNCs. Limit of detection is 1 copy/100,000 cell equivalents MNC DNA.
doi:10.1371/journal.pone.0023092.g009
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impact of TRIM5a genotype on SIVsmE660 kinetics in vivo, nor
any confounding impact on the outcome of the vaccine study.
However, this does not take into account potential differences in
TRIM5a gene expression in vivo in response to vaccination,
particularly as differences in vaccine kinetics between vaccinates
were noted. More detailed studies would be required to fully
resolve this issue. While it is possible that localised expression of
anti-retroviral restriction factors may be responsible for the failure
of B213 to generate a full infection response, more detailed
analyses of the transcriptome profile of this macaque would be
required to clarify why disseminated infection did not occur.
The striking observation of this study is the potent protection
conferred by SIVmacC8 against SIVsmE660 challenge after only
three weeks vaccination, which appears to be unrelated to any
confounding host genetic factors. A potent anti-retroviral state
appeared to be in place extremely rapidly, irrespective of widely
divergent genetic and antigenic variation between vaccine and
challenge strains. SIVmac251/C8 displays ,87%, 83% and 81%
nucleotide sequence similarity in gag, env and nef genes
respectively to SIVsm-related viruses, comparable to recently
described inter-clade differences between SIVmac251 and
SIVsmE660 [30]. While these observations do not take into
account the biological heterogeneity of different challenge isolates
used in challenge studies, the high levels of protection conferred by
SIVmacC8 in MCM against the SIVsmE660 stock may be
interpreted as representing a strong cross-clade vaccine effect.
This outcome differs from previous studies conducted in Indian
RM where vaccination with SIVmacD3 [29] or SIVmac239Dnef
[18] conferred limited protection against SIVsmE660 challenge. It
seems unlikely this could be due to the relative virulence of the
viral challenge since SIVsmE660 in MCM establishes a compa-
rably high peak and more persisting viraemia than in Indian RM
[18,29,30,50], which is not influenced by host genetics. Vaccine
studies with SIVmac239Dnef have also tended to show increasing
degrees of protection between 5 and 25 weeks post-vaccination
[9], compatible with maturing immunological responses after
prolonged vaccination. If differences in outcome are due to the
vaccine in the host, vaccination of MCM with SIVmac239Dnef
would enable an evaluation of this component of vaccine
protection. Characterisation of the vaccine escape viruses in this
study at early and late times post-SIVsmE660 challenge may also
provide clues as to the genetic composition of the viruses able to
evade this otherwise potent protection.
The potential for live attenuated SIV vaccines to achieve such
potent heterologous protection needs to be addressed when
considering hypotheses of protective mechanisms. Previous studies
of protection conferred by SIVmacC8 have not identified a central
role for adaptive immune responses detectable in the periphery
[24,25,8], in agreement with other studies [14,41]. Superinfection
resistance outcomes of reciprocal SIVmac251 and SIVsmE660
heterologous challenges further suggest protection is unlikely to be
mediated by peripheral adaptive immune responses [30]. Recent
studies conducted in MCM, however, while further confirming
high frequencies of functional CD8+ T-cell responses are not
induced in the peripheral blood after live attenuated SIV
vaccination, have detected CD8+ T cells recovered from mucosal
tissues, such as the lung, capable of suppressing virus after only 8
days [41]. Unfortunately, the design of the current study precluded
a formal investigation of mucosal-based immunity. Clearly,
whether the protective processes are the same for low-dose
mucosal SIVsmE660 challenge in this species would be an
important question to address.
However, our recent analyses of primary SIVmacC8 infection
focussing on early events in the gut mucosae, a primary site of
HIV/SIV replication [51–55], have shown the replication kinetics
of SIVmacC8 in MCM to have a profound impact on immune cell
population dynamics post-inoculation [56]. Intestinal lymphoid
cells expressing CD4+/CCR5+ receptors markedly depleted
following inoculation of SIVmacC8 at early times recover by 20
weeks, suggesting target cell depletion per se cannot account for
later protection [56]. In the RM model, maintenance of the
intestinal CD4+ memory T cell population has been associated
with vaccine protection independent of clear immune correlates of
protection [17]. Unravelling the relative contribution of early
changes in target cell dynamics in the gut mucosae and long term
changes, perhaps driven by persistence of the vaccine virus across
Table 3. Frequency of SIV RNA positive cells in protected, superinfected vaccinates and challenge controls by in situ hybridisation.
Group Identity Vaccine duration Weeks to ISH Frequency of SIV ISH +ve cells
Spl PLN MLN S.Int Thy
Protected B202 20 (A) 40 + + + + +
vaccinates B203 20 (A) 40 + + + + +
B205 20 (A) 40 + + + + +
B206 3 (B) 23 + + + + +
B207 3 (B) 23 + + + + +
B208 3 (B) 23 + + + + +
Superinfected B204 20 (A) 40 +++ + + + +
vaccinates B209 3 (B) 23 + + + + +
Challenge B210 (C) 20 + + ++ + +
controls B211 (C) 20 + + + + +
B212 (C) 20 +++ + ++ + +
B213 (C) 20 ++ + + ++ +
All vaccinates were challenged with the same dose of SIVsmE660 for the same duration (20 weeks); the total time to sampling is indicated by the vaccination duration of
20 or 3 weeks and group (A–C). The frequency of SIV positive (+ve) cells determined by in situ hybridisation (ISH) is shown for each tissue. Lymphoid tissues sampled
were spleen (Spl), peripheral and mesenteric lymph nodes (PLN, MLN), small intestine (S.Int) and thymus (Thy) collected post-mortem. A grading system of + (0.5–6.8),
++ (6.9–13.8) and +++ (.13.8) cells/mm3 was employed.
doi:10.1371/journal.pone.0023092.t003
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a wide number of body lymphoid compartments, will be important
to assess early and late vaccine responses. Differences in levels of
CCR5 expression between different species may also be a factor
when interpreting inter-species differences in outcome [56].
One consistent feature of live attenuated SIV vaccine studies is
that protection appears inversely proportional to the degree of
viral attenuation [13], more vigorous and persisting vaccine viruses
associated with higher levels of protection. Conversely, highly
attenuated viruses make very poor vaccines [57], with some SHIV-
based vaccines conferring more limited vaccine protection over
extended studies [58,59]. In this study, in protected vaccinates
SIVmacC8 persisted in a wide range of lymphoid tissues sampled
post-mortem including the spleen, peripheral and mesenteric
lymph nodes, small intestine and thymus indicated by a consistent
frequency of SIV RNA positive cells, widely distributed among
lymphoid organs. This characteristic feature of SIVmacC8
vaccination [8,10] may contribute to its ability to resist a range
of challenge viruses via different routes.
A direct role for an actively replicating retrovirus in live
attenuated SIV vaccine studies seems further supported by the fact
that protection against re-challenge can be associated with
significant re-stimulation of the vaccine virus [8,21]. Although
the levels of vaccine virus recrudescence detected in protected
vaccinates in this study were lower than previously reported when
re-challenged with a vigorously replicating homologous wild-type
virus [8]. Interestingly, vaccine virus re-stimulation was highest in
vaccinate B204 where simultaneous replication of the superinfect-
ing SIVsmE660 virus and co-stimulated vaccine virus were
Figure 10. Distribution of SIV RNA positive cells by ISH in protected/unprotected vaccinates and SIVsmE660 controls. Panels A and B)
Mesenteric lymph node (MLN) sections from 20 and 3 week SIVmacC8 vaccinates (B202 and B207) protected from SIVsmE660 challenge. Panels C and
D show spleen (spl) and MLN from 20 and 3 week SIVmacC8 vaccinates subsequently superinfected with SIVsmE660. B204 shows multiple foci of SIV
RNA positive cells in spleen. Panels E and F show MLN and small intestine (S.Int) sections of naive challenge control macaques B210 and B213 after 20
weeks SIVsmE660 infection. B213 exhibits occasional clusters of SIV positive cells. Black staining indicates foci of SIV infection as indicated by arrows.
doi:10.1371/journal.pone.0023092.g010
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detected together. Whether this is related to the more controlled
vRNA kinetics in the 20 weeks SIVmacC8 vaccination prior to
SIVsmE660 challenge is unclear (see Figure 3), but indicates
altered infection dynamics during the vaccination period in this
vaccinate. New vaccine tools, such as the conditionally live
attenuated SIVrtTA vaccine [60] where the kinetics of the vaccine
virus may be modulated, may provide further insight into the role
of vaccine persistence.
Concepts of vaccine protection centred around target cell
population dynamics, vaccine persistence and cell permissivity
post-vaccination focussed around localised vaccine-induced re-
sponses could account for the apparent paradox of superior
protection against heterologous virus challenge (SIVsmE660)
compared to more limited early protection against vigorous,
homologous wild-type virus challenge (SIVmac251/32H/L28
stock) [8]. Analysis of the early pathogenesis of these two distinct
virus stocks in vivo will further address this, since localisation of
virus by ISH suggests an altered distribution of virus between
protected vaccinates and challenge controls. Induction of localised
innate immune responses, perhaps driven by persisting SIV
replication at key sites of infection may also influence direct viral
competition [61]. The ability to derive potent protection against
SIVsmE660 as soon as 3 weeks post SIVmacC8 vaccination
augments earlier observations where time to protection studies
conferred by SIVmacC8 against wild-type virus challenge have
demonstrated an early protective effect in this model system,
which is partially protective as early as 10 days post-vaccination
[24]. As adaptive immune responses have so far not been found to
be central to this protection, we are considering whether innate
immune responses may be at play. This model will enable
evaluation of whether an up-regulation of interferon-inducible
anti-retroviral restriction factors [62,63] which, for example, may
be contributing to a state of retroviral superinfection resistance in
vivo or whether some other anti-viral interference mechanism is
responsible for the protection observed. Determining the relative
contributions of innate and adaptive immune responses in this
mode of vaccine protection will be important to better our
understanding of this potent vaccine approach.
In summary, early, potent protection against a vigorously
replicating, heterologous viral challenge (SIVsmE660) was dem-
onstrated in Mauritian-origin cynomolgus macaques. Using this
genetically characterised model, potent vaccine protection was
generated by administration of a persisting live attenuated SIV for
three weeks. Defining how this works will inform the field whether
it can be harnessed to aid development of effective AIDS vaccines
for clinical use.
Materials and Methods
Virus stocks
The SIVsmE660 challenge stock was obtained courtesy of Dr.
Vanessa Hirsch and Dr. Philip Johnson through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, USA, originally derived from spleen cells of a rhesus
macaque inoculated with blood from RhE543, a SIVsmF236-
infected rhesus macaque [64]. SIVsmE660 was selected since it
represents a pathogenic, uncloned virus stock, considered to be a
heterologous isolate with respect to SIVmac239/SIVmac251
viruses which replicates in lymphocytes and macrophages.
Independent titration experiments with this stock were performed
to determine the infectivity and end-point titre of the SIVsmE660
challenge stock in naı¨ve cynomolgus macaques, used directly as
supplied, with no further passage or adaptation in cynomolgus
macaques or cynomolgus PBMCs in vitro.
The vaccine virus, SIVmacC8, is a virus clone characterised to
have an attenuated phenotype in vivo, the result of a 12bp (4
amino acid) in-frame deletion in nef and two additional
conservative amino acid changes [35]. In the vaccine study,
macaques were inoculated intravenously with 5000 TCID50
SIVmacC8 (9/90 pool).
Ethics statement
The non-human primates in this study were used in strict
accordance with UK Home Office guidelines. The work at NIBSC
was governed by the Animals (Scientific Procedures) Act 1986
which complies with the EC Directive 86/609. The work was
performed under licence PPL 80/1952 which was granted only
after review of all the procedures in the licence by the local Ethical
Review Process (ERP) at NIBSC.
All individuals in the study were purpose bred and group
housed for the entire duration of the study. Regular modifications
to the housing area including the introduction of novel structures
and the introduction of foodstuffs in novel manners were made by
husbandry staff to enrich the environment during the study. All
animals were sedated prior to bleeding or inoculation of virus by
venepuncture. Regular, frequent checks were made by staff and
any unexpected change in behaviour by individuals on study
followed up, including seeking of veterinary advice where
necessary. Regular blood samples were obtained to assess
haematological parameters in blood that might provide evidence
of incipient disease and veterinary advice was sought when
persisting abnormalities detected. The study was terminated and
all animals killed humanely by administering an overdose of
anaesthetic prior to the development of overt symptoms of disease.
All efforts were made to minimise suffering.
Experimental outline
Twenty-six naı¨ve, simian D-type retrovirus free, juvenile
Mauritian cynomolgus macaques (Macaca fascicularis) were used.
In vivo titration of the SIVsmE660 stock was performed in two
series by intravenous inoculation of a total of 14 naive MCM.
Dilutions of the SIVsmE660 challenge stock were prepared
directly from the NIH stock, without any onward passage, in
RPMI 1640 media, in ten-fold steps. Initially, four groups of two
macaques were used (Group 1, B1, B2; Group 2, B3, B4; Group 3,
B5, B6; Group 4, B7, B8) bled at 0, 7, 10, 14, 21, 28, 54, 86 and
140 days post-infection (p.i). and a further six to establish the final
end-point (Group 5, B95, B96; Group 6, B97, B98; Group 7, B99,
B100) bled at 14, 28, 54, 86 and 140 days p.i.
The vaccine study comprised three groups of four MCM,
vaccinated with 5000 TCID50 SIVmacC8 [35], either for 20
weeks (B202–B205; Group A) or 3 weeks (B206–B209; Group B).
Twenty week vaccinates were bled at intervals post-SIVmacC8
inoculation (0, 14, 21, 56 and 140 days) and 3 week vaccinates at 0
and 21 days post-vaccination. All vaccinates were challenged with
10 MID50 (MID50 = macaque infectious dose where 50% of
macaques are infected) of SIVsmE660 challenge stock with four
additional naı¨ve challenge controls (B210–B213; Group C) in the
vaccine study bled at 0, 14, 28, 54, 84, 112 days post-SIVsmE660
challenge, euthanased humanely at ,140 days post-infection.
Real time QPCR to quantify total SIV RNA levels in plasma
Total plasma SIV RNA levels in naive MCM challenged with
dilutions of the NIH SIVsmE660 challenge stock in the in vivo
titration were assessed by quantitative real-time PCR. Using
conserved sequences located in the R/U5 region of genomic SIV
RNA, an assay was developed using a previously validated SIV
RNA reference panel [65]. Viral RNA was extracted from 140 ml
Heterologous SIV Vaccine Protection
PLoS ONE | www.plosone.org 15 August 2011 | Volume 6 | Issue 8 | e23092
plasma using viral RNA mini-kits (QIAamp; Qiagen) according to
the manufacturer’s instructions, eluted in a final volume of 50 ml
AVE elution buffer. RNA (5 ml) extracted from reference or
experimental samples were amplified, in triplicate, using Ultra-
Sense one-step RT-PCR kits (Invitrogen Ltd). The R/U5 qRT-
PCR assay was performed with forward primer: (59-CTCCAC-
GCTTGCTTGCTTAA-39), reverse primer (59-AGGGTCCTA-
ACAGACCAGGG-39) and Taqman hydrolysis probe sequence
(59-69-TCCCATATCTCTCCTAGYCGCCGC-39-BHQ1). Op-
timised thermal cycling profiles were 51C/30mins for the RT
step, inactivation/activation step at 95C/10 mins, and 45 cycles of
denaturation (95C/30sec), and annealing/elongation (60C/90sec)
performed on an Mx3000P genetic analyser (Stratagene Ltd).
Quantitative data were determined using the Mx3000P software.
The assay had a lower limit of detection of 50 SIV RNA copies/ml
plasma.
Amplification and sequencing of SIV gag
PCR amplification of,700bp region of SIV gag was performed
on DNA template derived from unvaccinated macaques chal-
lenged with the SIVsmE660 challenge stock using nested PCR
primers: forward/outer (59-ATGGGCGCGAGAAACTCCGTC-
39) reverse/outer (59-CTACTGGTCTCCTCCAAAGAG-39) for-
ward/inner (59-AACAAGTAGACCAACAGCAC-39) reverse, in-
ner (59-TCCCCTCTGTTGGACTGCT-39). Amplification prod-
ucts were diluted 1:15 and sequenced as previously described [8].
Sequences were assembled, aligned and compared with published
database sequences for SIVmac/sm strains (www.hiv.lanl.gov).
Detection and differentiation of SIVmacC8 and
SIVsmE660 by PCR
Real-time PCR assays which differentiate between the vaccine
(SIVmacC8) and challenge (SIVsmE660) viruses were applied to
plasma and PBMC purified from peripheral blood and mononu-
clear cells (MNCs) derived from lymphoid tissues (spleen, MLN,
PLN) collected post-mortem. SIVmacC8 was detected using the
gag assay as previously described [8]. An analogous assay was
developed by modification of primers to detect SIVsmE660
sequences, but not SIVmac251/C8.
Optimised SIVsmE660-specific primer/probe combinations in gag
yielded a 75bp amplicon: 50nm SIVsmE660-specific forward primer
(59-GCTGCCGATTGGGATTTACA-39), 900nM SIVsmE660-spe-
cific reverse primer (59-GTCTGATCCTCTTGGCTCTCTAA-
GTT-39); 75nM SIVsmE660 specific probe sequence (59FAM-
CGCAGCCAGGTCCACTACCAGCA-39-BHQ1). Amplifications
for vRNA analysis were performed using Ultrasense one-step RT-
PCR kits (Invitrogen) with 5 ml RNA. Cycling conditions were 30sec/
54C (reverse transcription), hot start 10min/95C and a two-step
amplification of 30sec/95C and 90sec/60C for 45 cycles performed on
a Stratagene Mx3005P thermal cycler.
Virological and serological assays
Virus isolation was performed on Ficoll-purified PBMC
following 28 days co-culture with C8166 indicator cells, evidence
of virus replication by syncitium formation and p27 antigen
detection [66]. Anti-gp130 levels were determined by enzyme
immunoassay [25], with SIV envelope rgp130 (EVA670/CFAR/
NIBSC) antigen. Neutralizing antibody titres were determined by
mixing serum serially diluted in RPMI containing 10% FCS with
virus. Serum dilutions representing 75% inhibition p27 antigen
production represented the titre. SIVsmE660 challenge stock was
used directly to assess neutralising antibodies against the challenge
virus and SIVmac251/J5 to represent the vaccine virus.
Immunological and haematological analyses
CD3+/CD4+ and CD3+/CD8+ lymphocyte populations were
monitored in whole blood by flow cytometry following immuno-
staining with cross-reactive anti-human monoclonal antibodies.
Whole blood (200 ml) was incubated with 10 ml of fluorescein
isothiocyanate (FITC)-labelled anti-monkey CD3 monoclonal
antibody, FN18 (Serotec), 20 ml of phycoerythrin (PE)-labelled
anti-human CD4 monoclonal antibody, Leu-3a (BD Biosciences),
10 ml of APC-labelled anti-human CD8 monoclonal antibody,
3B5 (Caltag), 1hr 4C. FACS lysing solution (BD Biosciences) was
used to remove red blood cells; cells were washed twice (PBS
containing 4% (v/v) FCS/0.1% sodium azide). Samples were
analysed by FACS (FACSCalibur, BD Biosciences), after fixing
cells overnight in 2% (v/v) formaldehyde in PBS, gating on the
lymphocyte fraction.
In situ hybridization analyses
In situ hybridisation (ISH) was performed on lymphoid tissues
(spleen, MLN, PLN, small intestine, thymus) collected post-
mortem as previously described [67]. Hybridisation mixes
consisted of sense or anti-sense probes to SIV gag, env and nef
transcripts. Quantitative ISH data were determined by manually
counting positive cells within up to 10 random fields of view (x10
lens and x10 eye-piece magnification; equivalent to an area of
2.2mm2). The mean number of positive cells/mm2 was expressed
using a grading key (see Table 3).
MHC class IA and IB and II haplotype characterisation of
Mauritian cynomolgus macaques
MHC class IA and IB and class II haplotypes in Mauritian
cynomolgus macaques were determined by microsatellite PCR
with resolution of recombinant haplotypes by allele-specific PCR
as previously described [44].
Sequence analysis of TRIM5a
An 847-bp TRIM5a gene fragment encompassing the B30.2
domain (exon 8) was amplified from 200 ng genomic DNA in
25 ml reactions comprising: 10 mM Tris-HCl, pH 8.3; 50 mM
KCl; 2 mM MgCl2; 0.5 mM of each oligonucleotide (TRIM5-Ex8-
S, 59-GTA AGG AGA AGT CAC ATT ATC A- 39 and TRIM5-
Ex8-A, 59-TCA AGA GCT TGG TGA GCA CAG-39); 0.2 mM
each of dATP, dCTP, dGTP and dTTP and 1.25 U AmpliTaq
Gold DNA polymerase (Applied Biosystems, USA). Amplification
consisted of a single cycle at 94C/2 min, followed by 39 cycles
comprising 94C/30 sec, 64C/45 sec, 72C/2 min and a single
5 min incubation at 72C. For each sample two independently
amplified fragments were bi-directionally sequenced using BigDye
Terminator v3.1 cycle sequencing (Applied Biosystems, Cheshire,
UK). Sequences were aligned and analysed using MEGA Version 4
[68].
Statistical analyses
Data were presented graphically using Sigma Plot version 8.0
(SPSS Inc). Standard error determinations of mean (6 SE) viral
RNA copy number and comparison of plasma viral load (SIV
RNA copies/ml) between vaccinated and naı¨ve challenge
macaques by nonparametric Mann-Whitney t test, were per-
formed using MiniTab (version 15) software.
Supporting Information
Table S1 Concordant outcome in productive infection
by vRNA and virus isolation in MCM challenged with
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serial dilutions of the SIVsmE660 challenge stock. Nt =
not tested. The number of infected macaques is shown for each
pair of macaques challenged. vRNA = viral RNA; VI = virus
isolation.
(PDF)
Acknowledgments
Thanks to David North and Jo Hall for their technical skills and expertise
and Martin Cranage for discussions.
Author Contributions
Conceived and designed the experiments: NB NA RS. Performed the
experiments: CH ETM GM AJ MP WE MR DS DF. Analyzed the data:
NB ETM NJR GM MP DF GT NA RS. Wrote the paper: NB NA RS.
References
1. Barouch DH, Korber B (2010) HIV-1 vaccine development after STEP Ann
Rev Med. 61: 153–167.
2. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity
considerations in HIV-1 vaccine selection. Science 296: 2354–2360.
3. McCutchan FE (2006) Global epidemiology of HIV. J Med Virol 78: S7–S12.
4. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV
vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7:
19–23.
5. Abel K, Compton L, Rourke T, Montefiori D, Lu D, et al. (2003) Simian-human
immunodeficiency virus SHIV89.6-induced protection against intravaginal
challenge with pathogenic SIVmac239 is independent of the route of
immunization and is associated with a combination of cytotoxic T-lymphocyte
and alpha interferon responses. J Virol 77: 3099–3118.
6. Ahmed RK, Nilsson C, Wang Y, Lehner T, Biberfeld G, et al. (1999) Beta-
chemokine production in macaques vaccinated with live attenuated virus
correlates with protection against simian immunodeficiency virus (SIVsm)
challenge. J Gen Virol 80: 1569–1574.
7. Almond N, Kent K, Cranage M, Rud E, Clarke B, et al. (1995) Protection by
attenuated simian immunodeficiency virus in macaques against challenge with
virus-infected cells. Lancet 345: 1342–1344.
8. Berry N, Stebbings R, Ferguson D, Ham C, Alden J, et al. (2008) Resistance to
superinfection by a vigorously replicating, uncloned stock of simian immuno-
deficiency virus (SIVmac251) stimulates replication of a live attenuated virus
vaccine (SIVmacC8). J Gen Virol 89: 2240–2251.
9. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, et al. (1998)
Temporal analyses of virus replication, immune responses, and efficacy in rhesus
macaques immunized with a live, attenuated simian immunodeficiency virus
vaccine. J Virol 72: 7501–7509.
10. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, et al. (1997)
Macaques infected with live attenuated SIVmac are protected against
superinfection via the rectal mucosa. Virology 229: 143–154.
11. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992)
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.
Science 258: 1938–1941.
12. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, et al. (1997) Induction
of vigorous cytotoxic T-lymphocyte responses by live attenuated simian
immunodeficiency virus. J Virol 71: 7711–7718.
13. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, et al. (1999) Highly
attenuated vaccine strains of simian immunodeficiency virus protect against
vaginal challenge: inverse relationship of degree of protection with level of
attenuation. J Virol 73: 4952–4961.
14. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, et al. (2008)
Vaccine protection by live, attenuated simian immunodeficiency virus in the
absence of high-titer antibody responses and high-frequency cellular immune
responses measurable in the periphery. J Virol 82: 4135–4148.
15. Nilsson C, Makitalo B, Thorstensson R, Norley S, Binninger-Schinzel D, et al.
(1998) Live attenuated simian immunodeficiency virus (SIV)mac in macaques
can induce protection against mucosal infection with SIVsm. AIDS 12:
2261–2270.
16. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R (1996) Protection
from pathogenic SIVmac challenge following short-term infection with a nef-
deficient attenuated virus. Virology 219: 195–205.
17. Pahar B, Lackner AA, Piatak M Jr., Lifson JD, Wang X, et al. (2009) Control of
viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3)
infected macaques after pathogenic SIV(MAC251) challenge. Virology 387:
273–284.
18. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al.
(2008) Macaques vaccinated with live-attenuated SIV control replication of
heterologous virus. J Exp Med 205: 2537–2550.
19. Schmitz JE, Johnson PR, McClure H, Manson KM, Wyand M, et al. (2005)
Effect of CD8+ lymphocyte depletion on virus containment after simian
immunodeficiency virus SIVmac251 challenge of live attenuated SIV-
mac239D3-vaccinated rhesus macaques. J Virol 79: 8131–8141.
20. Sharpe SA, Whatmore AM, Hall GA, Cranage MP (1997) Macaques infected
with attenuated simian immunodeficiency virus resist superinfection with
virulence-revertant virus. J Gen Virol 78: 1923–1927.
21. Sharpe S, Cope A, Dowall S, Berry N, Ham C, et al. (2004) Macaques infected
long-term with attenuated simian immunodeficiency virus (SIVmac) remain
resistant to superinfection despite declining cytotoxic T lymphocyte responses to
an immunodominant epitope. J Gen Virol 85: 2591–2602.
22. Stahl-Hennig C, Dittmer U, Nisslein T, Petry H, Jurkiewicz E, et al. (1996)
Rapid development of vaccine protection in macaques by live-attenuated simian
immunodeficiency virus. J Gen Virol 77: 2969–2981.
23. Stebbings R, Stott J, Almond N, Hull R, Lines J, et al. (1998) Mechanisms of
protection induced by attenuated simian immunodeficiency virus. II. Lympho-
cyte depletion does not abrogate protection. AIDS Res Hum Retroviruses 14:
1187–1198.
24. Stebbings R, Berry N, Stott J, Hull R, Walker B, et al. (2004) Vaccination with
live attenuated simian immunodeficiency virus for 21 days protects against
superinfection. Virology 330: 249–260.
25. Stebbings R, Berry N, Waldmann H, Bird P, Hale G, et al. (2005) CD8+
lymphocytes do not mediate early protection against superinfection by
inoculation with a live attenuated simian immunodeficiency virus. J Virol 79:
12264–12272.
26. Titti F, Sernicola L, Geraci A, Panzini G, Di Fabio S, et al. (1997) Live
attenuated simian immunodeficiency virus prevents super-infection by cloned
SIVmac251 in cynomolgus monkeys. J Gen Virol 78: 2529–2539.
27. Walther-Jallow L, Nilsson C, So¨derlund J, ten Haaft P, Ma¨kitalo B, et al. (2001)
Cross-protection against mucosal simian immunodeficiency virus (SIVsm)
challenge in human immunodeficiency virus type 2-vaccinated cynomolgus
monkeys. J Gen Virol 82: 1601–1612.
28. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, et al. (1995) Repair and
evolution of nef in vivo modulates simian immunodeficiency virus virulence.
J Virol 69: 5117–5123.
29. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, et al. (1999)
Protection by live, attenuated simian immunodeficiency virus against heterol-
ogous challenge. J Virol 73: 8356–8363.
30. Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, et al. (2009)
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus
monkeys against superinfection with a heterologous SIV isolate. J Virol 83:
2686–2696.
31. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, et al. (1995)
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal
macaques. Science 267: 1820–1825.
32. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live
attenuated, multiply deleted simian immunodeficiency virus causes AIDS in
infant and adult macaques. Nat Med 5: 1–10.
33. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM,
et al. (2003) Live attenuated, nef-deleted SIV is pathogenic in most adult
macaques after prolonged observation. AIDS 17: 157–166.
34. Gundlach BR, Lewis MG, Sopper S, Schnell T, Sodroski J, et al. (2000)
Evidence for recombination of live, attenuated immunodeficiency virus vaccine
with challenge virus to a more virulent strain. J Virol 74: 3537–3542.
35. Rud EW, Cranage M, Yon J, Quirk J, Ogilvie L, et al. (1994) Molecular and
biological characterization of simian immunodeficiency virus macaque strain
32H proviral clones containing nef size variants. J Gen Virol 75: 529–543.
36. Almond N, Rose J, Sangster R, Silvera P, Stebbings R, et al. (1997) Mechanisms
of protection induced by attenuated simian immunodeficiency virus. I.
Protection cannot be transferred with immune serum. J Gen Virol 78:
1919–1922.
37. Krebs KC, Jin Z, Rudersdorf R, Hughes AL, O’Connor DH (2005) Unusually
high frequency MHC class I alleles in Mauritian origin cynomolgus macaques.
J Immunol 175: 5230–5239.
38. O’Connor SL, Blasky AJ, Pendley CJ, Becker EA, Wiseman RW, et al. (2007)
Comprehensive characterization of MHC class II haplotypes in Mauritian
cynomolgus macaques. Immunogenetics 59: 449–462.
39. Wiseman RW, Wojcechowskyj JA, Greene JM, Blasky AJ, Gopon T, et al.
(2007) Simian immunodeficiency virus SIVmac239 infection of major
histocompatibility complex-identical cynomolgus macaques from Mauritius.
J Virol 81: 349–61.
40. O’Connor S, Lhost JL, Becker EA, Detmer AM, Johmson RC, et al. (2010)
MHC heterozygote advantage in simian immunodeficiency virus-infected
Mauritian cynomolgus macaques. Sci Trans Med 2: 22ra18.
41. Greene JM, Lhost JL, Burwitz BJ, Budde ML, Macnair CE, et al. (2010)
Extralymphoid CD8+ T cells resident in tissues from simian immunodeficiency
Heterologous SIV Vaccine Protection
PLoS ONE | www.plosone.org 17 August 2011 | Volume 6 | Issue 8 | e23092
virus SIVmac239Dnef-vaccinated macaques suppress SIVmac239 replication ex
vivo. J Virol 84(7): 3362–3372.
42. Greene JM, Burwitz BJ, Blasky AJ, Mattila TL, Hong JJ, et al. (2008) Allogeneic
lymphocytes persist and traffic in feral MHC-matched Mauritian cynomolgus
macaques. PLoS ONE 3: e2384.
43. Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, et al. (2008)
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and
Indian rhesus macaques: influence of Mauritian MHC haplotypes on
susceptibility/resistance to SHIV(89.6P) infection. Vaccine 26: 3312–3321.
44. Mee ET, Berry N, Ham C, Sauermann U, Maggiorella MT, et al. (2009) Mhc
haplotype H6 is associated with sustained control of SIVmac251 infection in
Mauritian cynomolgus macaques. Immunogenetics 61: 327–339.
45. Mee ET, Berry N, Ham C, Aubertin A, Lines J, et al. (2010) Mhc haplotype M3
is associated with early control of SHIVsbg infection in Mauritian cynomolgus
macaques. Tissue Antigens 76: 223–229.
46. Newman RM, Hall L, Kirmaier A, Pozzi L-A, Pery E, et al. (2008) Evolution of
a TRIM5-CypA Splice Isoform in Old World Monkeys. PLoS Pathog 4:
e1000003.
47. Clarke S, Almond N, Berry N (2003) Simian immunodeficiency virus Nef gene
regulates the production of 2-LTR circles in vivo. Virology 306: 100–108.
48. Lim S-Y, Rogers T, Chan T, Whitney JB, Kim J, et al. (2010) TRIM5alpha
modulates immunodeficiency virus control in rhesus monkeys. PLOS Path 6:
e1000738.
49. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, et al. (2010) TRIM5
suppresses cross-species transmission of a primate immunodeficiency virus and
selects for emergence of resistant variants in the new species. PLoS Biol 24;8 (8).
pii: e1000462.
50. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, et al. (2009)
Vaccine-induced cellular responses control simian immunodeficiency virus
replication after heterologous challenge. J Virol 83: 6508–6521.
51. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998)
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral
replication in SIV infection. Science 280: 427–431.
52. Veazey RS, Mansfield KG, Tham IC, Carville AC, Shvetz DE, et al. (2000)
Dynamics of CCR5 expression by CD4+ T cells in lymphoid tissues during
simian immunodeficiency virus infection. J Virol 74: 11001–11007.
53. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+
T cell depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J Exp Med 200: 749–759.
54. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in
resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature
434: 1148–1152.
55. Mattapillil JL, Douek D, Hill B, Nishimura Y, Martin M, et al. (2005) Massive
infection and loss of memory CD4+ T cells in multiple tissues during acute SIV
infection. Nature 434: 1093–1097.
56. Li B, Berry N, Ham C, Ferguson D, Smith D, et al. (2011) Vaccination with live
attenuated simian immunodeficiency virus causes dynamic changes in intestinal
CD4+CCR5+ T cells Retrovirology 8: 8.
57. Alexander L, Illyinskii PO, Lang SM, Means RE, Lifson J, et al. (2003)
Determinants of increased replicative capacity of serially passaged simian
immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 77:
6823–6835.
58. Kumar AZ, Liu D, Sheffer M, Smith DK, Singh S, et al. (2008) Protection of
macaques against AIDS with a live attenuated SHIV vaccine is of finite
duration, Virology. 371: 238–245.
59. Yankee TM, Sheffer D, Liu Z, Dhillon S, Jia F, et al. (2009) Longitudinal study
to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term
immunized rhesus macaques. Virology 383: 103–111.
60. Das AT, Klaver B, Centlivre M, Harwig A, Ooms M, et al. (2008) Optimization
of the doxycycline-dependent simian immunodeficiency virus through in vitro
evolution. Retrovirology 5: 44.
61. Wodarz D (2008) Immunity and protection by live attenuated HIV/SIV
vaccines. Virology 378: 299–305.
62. Huthoff H, Towers GJ (2008) Restriction of retroviral replication by
APOBEC3G/F and TRIM5alpha. Trends Microbiol 16: 612–619.
63. Neil S, Bieniasz P (2009) Human immunodeficiency virus, restriction factors,
and interferon. J Interferon Cytokine Res 29: 569–580.
64. Hirsch VM, Johnson PR (1994) Pathogenic diversity of simian immunodefi-
ciency viruses. Virus Res 32: 183–203.
65. Ham C, Srinivasan P, Thorstensson R, Vershoor E, Vagrouche Z, et al. (2010)
An International multi-centre study to assess a panel of reference materials for
SIV RNA quantification. J Clin Micro 48: 2582–2585.
66. Silvera P, Wade-Evans A, Rud E, Hull R, Silvera K, et al. (2001) Mechanisms of
protection induced by live attenuated simian immunodeficiency virus: III. Viral
interference and the role of CD8+ T-cells and beta-chemokines in the inhibition
of virus infection of PBMCs in vitro. J Med Primatol 30: 1–13.
67. Canto-Nogues C, Jones S, Sangster R, Silvera P, Hull R, et al. (2001) In situ
hybridization and immunolabelling study of the early replication of simian
immunodeficiency virus (SIVmacJ5) in vivo. J Gen Virol 82: 2225–2234.
68. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24(8):
1596–1599.
Heterologous SIV Vaccine Protection
PLoS ONE | www.plosone.org 18 August 2011 | Volume 6 | Issue 8 | e23092
